POST Online Media Lite Edition



 

Oncimmune appoints James Jett as chief medical officer

Staff writer |
Nottingham, United Kingdom - Oncimmune, an early cancer detection company, announced the appointment of James Jett, as chief medical officer.

Article continues below




Dr. Jett is currently Professor of Medicine in the Division of Oncology at National Jewish Health in the USA, where his research includes conducting clinical trials related to the screening and early detection of lung cancer.

Prior to joining National Jewish Health in 2010, he held appointments as Professor of Medicine at Mayo Medical School and the University of Pittsburgh.

Dr. Jett’s research interests focus on the screening and early detection of lung cancer.

His research has been funded by the National Institutes of Health and the National Cancer Institute and he was part of a research team that discovered how CT screening can be an effective tool to detect lung cancer early in high-risk patients.

Dr. Jett is board certified in internal medicine and pulmonary medicine, and he completed his medical degree at the University of Missouri, Columbia.

He completed a residency in internal medicine and a fellowship in thoracic diseases at Mayo Graduate School of Medicine, and a research fellowship at the National Cancer Institute, National Institutes of Health.

He is on the Scientific Advisory Committee for the American Lung Association and was an External Review Chair for the Terry Fox Research Institute, Lung Cancer Grant.

Dr. Jett has served in journal review and editorial activities for many medical publications, including the American Journal of Respiratory and Critical Care Medicine, American Journal of the Medical Sciences, Cancer, Chest, International Journal of Cancer, Lung Cancer and The New England Journal of Medicine.

 LATEST MOVES FROM United Kingdom 

Halfords appoints Jo Hartley as CFO
Ace Aquatec appoints Duncan Montgomery as CFO
Grayshift: Digital forensics industry veteran Paul Baxter to lead Europe team
PZ Cussons appoints Valeria Juarez as director
BT appoints Adam Crozier as chairman

What to read next

Oncimmune Holdings appoints Carsten Schroeder as director
Oncimmune Holdings appoints Andrew Millet as CFO
Oncimmune appoints Julian Hirst as non-executive director